Literature DB >> 9100184

Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain.

J Devulder1.   

Abstract

The patient had lower lumbar arachnoiditis as part of a failed back surgery syndrome. Two years after discectomy, she still suffered from left lumbosciatic pain despite various invasive treatments. Psychologic impairment could be excluded. Finally, intrathecal morphine was infused at the D12 level. Small amounts of morphine (500-750 mg daily) introduced intolerable vomiting, which could not be prevented by antiemetics, so intrathecal sufentanil was started. A daily dose of 25 mg of sufentanil diluted in 1.5 ml of saline evoked hyperalgesia in the lower part of the body. Increasing the dose to 50 mg daily could only be supported for 3 h. Sufentanil was stopped and saline started, after which the evoked hyperalgesia disappeared. It is concluded that relatively high doses of sufentanil may induce hyperalgesia in patients with arachnoiditis and neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9100184     DOI: 10.1097/00008506-199704000-00007

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  22 in total

1.  Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance.

Authors:  T W Vanderah; N M Suenaga; M H Ossipov; T P Malan; J Lai; F Porreca
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

2.  Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process.

Authors:  E Célèrier; J P Laulin; J B Corcuff; M Le Moal; G Simonnet
Journal:  J Neurosci       Date:  2001-06-01       Impact factor: 6.167

3.  Opioid-induced long-term potentiation in the spinal cord is a presynaptic event.

Authors:  Hong-Yi Zhou; Shao-Rui Chen; Hong Chen; Hui-Lin Pan
Journal:  J Neurosci       Date:  2010-03-24       Impact factor: 6.167

Review 4.  Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.

Authors:  Daniel P Alford; Peggy Compton; Jeffrey H Samet
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

Review 5.  Medication overuse headache in patients with primary headache disorders: epidemiology, management and pathogenesis.

Authors:  Andrew J Dowson; David W Dodick; Volker Limmroth
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

6.  Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance.

Authors:  T W Vanderah; L R Gardell; S E Burgess; M Ibrahim; A Dogrul; C M Zhong; E T Zhang; T P Malan; M H Ossipov; J Lai; F Porreca
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

7.  Opioid-induced hypernociception is associated with hyperexcitability and altered tetrodotoxin-resistant Na+ channel function of dorsal root ganglia.

Authors:  Gracious R Ross; Aravind R Gade; William L Dewey; Hamid I Akbarali
Journal:  Am J Physiol Cell Physiol       Date:  2011-12-21       Impact factor: 4.249

8.  Altered quantitative sensory testing outcome in subjects with opioid therapy.

Authors:  Lucy Chen; Charlene Malarick; Lindsey Seefeld; Shuxing Wang; Mary Houghton; Jianren Mao
Journal:  Pain       Date:  2009-02-23       Impact factor: 6.961

9.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

10.  Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice.

Authors:  Carolina Muscoli; Salvatore Cuzzocrea; Michael M Ndengele; Vincenzo Mollace; Frank Porreca; Francesca Fabrizi; Emanuela Esposito; Emanuela Masini; George M Matuschak; Daniela Salvemini
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.